| Date | Time | Source | Headline | Symbol | Company |
| 03/02/2011 | 5:08PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/02/2011 | 5:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/02/2011 | 5:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/02/2011 | 5:04PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/25/2011 | 5:30PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/25/2011 | 5:29PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/25/2011 | 5:28PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/25/2011 | 5:28PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/25/2011 | 5:26PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/25/2011 | 5:26PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/17/2011 | 9:00AM | Business Wire | Allos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/14/2011 | 4:40PM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/14/2011 | 3:08PM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/10/2011 | 2:37PM | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/10/2011 | 6:02AM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/10/2011 | 6:02AM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/19/2011 | 6:31PM | Business Wire | Journal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN® in Relapsed or Refractory Perip... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/11/2011 | 8:04AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/11/2011 | 8:00AM | Business Wire | Allos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business Priorities | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/04/2011 | 4:56PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/21/2010 | 4:36PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/21/2010 | 8:00AM | Business Wire | Allos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/20/2010 | 8:00AM | Business Wire | Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/10/2010 | 3:15PM | Business Wire | New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/05/2010 | 9:00AM | Business Wire | Updated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Ly... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/04/2010 | 9:00AM | Business Wire | Allos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/04/2010 | 9:00AM | Business Wire | New Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis Fungoides | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/01/2010 | 8:00AM | Business Wire | Allos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/19/2010 | 8:00AM | Business Wire | New FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/04/2010 | 4:10PM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |